Slingshot members are tracking this event:

Aimmune (AIMT) to Complete Up-dosing of Peanut Allergy Patients Taking AR101 in Phase 3 PALISADE Trial in H1 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 06, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Up-dosing, Peanut Allergies, Ar101, Phase 3 Palisade Trial